Is myelin basic protein a potential biomarker of brain cancer?

被引：7
|
作者：
Zavialova, M. G. [1 ]
Shevchenko, V. E. [2 ]
Nikolaev, E. N. [1 ,3 ]
Zgoda, V. G. [1 ]
机构：
[1] Inst Biomed Chem IBMC, Moscow, Russia
[2] Blokhin Russian Canc Res Ctr, Moscow, Russia
[3] Skolkovo Inst Sci & Technol Skoltech, Skolkovo, Russia
来源：
EUROPEAN JOURNAL OF MASS SPECTROMETRY | 2017年 / 23卷 / 04期
基金：
俄罗斯科学基金会;
关键词：
Proteomics; pseudo-selected reaction monitoring; brain cancer; cerebral spinal fluid; myelin basic protein; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; QUANTITATIVE PROTEOMICS; IDENTIFICATION; DISEASE; SAMPLES; DAMAGE;
D O I：
10.1177/1469066717719810
中图分类号：
O64 [物理化学（理论化学）、化学物理学]; O56 [分子物理学、原子物理学];
学科分类号：
070203 ; 070304 ; 081704 ; 1406 ;
摘要：
Myelin basic protein is a potential biomarker for the central nervous system diseases in which the myelin sheath is destroyed. Using pseudo-selected reaction monitoring and the method of standard additions, we have measured the myelin basic protein level in the cerebrospinal fluid of patients with neurotrauma (n = 6), chronic neurodegenerative diseases (n = 2) and brain cancer (n = 5). Myelin basic protein was detected only in four out of five cerebrospinal fluid samples of patients with brain cancer. The cerebrospinal fluid myelin basic protein level ranged from 3.7 to 8.8 ng ml(-1). We suggest that monitoring of myelin basic protein in cerebrospinal fluid can serve as a diagnostic test for the brain cancer.
引用
收藏
页码：192 / 196
页数：5
相关论文
共 50 条
12345